Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RHEB | Q15382 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 3/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.44 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.44 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 3/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | CETP | P11597 | 2/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30343731 | 1.00 | KDM4E (0.47) | KDM4ENPC1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL21017252 | 0.87 | KDM4E (0.54) | KDM4ENPC1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL30343725 | 0.81 | NPBWR1 (0.50) | KDM4ENPC1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL19994514 | 0.81 | NPBWR1 (0.50) | KDM4ENPC1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL30343743 | 0.81 | RHEB (0.56) | KDM4ERHEBPKN1PKN2DGAT1 | |
| SCHEMBL20001680 | 0.81 | RHEB (0.56) | KDM4ERHEBPKN1PKN2DGAT1 | |
| SCHEMBL21017850 | 0.80 | KDM4E (0.49) | KDM4ENPC1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL20982629 | 0.77 | EGLN1 (0.51) | KDM4ENPC1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL1842216 | 0.77 | PKN1 (0.59) | KDM4ENPC1RAB9ASMN1; SMN2RHEB | |
| SCHEMBL1842081 | 0.77 | RHEB (0.59) | KDM4ENPC1RAB9ASMN1; SMN2RHEB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509465-B2 | Benzoimidazole derivatives as anticancer agents | CENTRE LEON BERARD (FR) | 2025-12-30 | — | — | US | disclosed |
| EP-3515904-B1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2024-01-17 | — | — | EP | disclosed |
| EP-3515904-B1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2024-01-17 | — | — | EP | disclosed |
| CN-110234640-B | Benzimidazole derivatives as anticancer agents | 利昂贝拉尔中心 | 2023-04-07 | — | — | CN | disclosed |
| US-20220348587-A1 | Benzoimidazole Derivatives As Anticancer Agents | CENTRE LEON BERARD (FR) | 2022-11-03 | — | — | US | disclosed |
| US-20220348587-A1 | Benzoimidazole Derivatives As Anticancer Agents | CENTRE LEON BERARD (FR) | 2022-11-03 | — | — | US | disclosed |
| US-11384081-B2 | Benzoimidazole derivatives as anticancer agents | CENTRE LEON BERARD (FR) | 2022-07-12 | — | — | US | disclosed |
| US-11384081-B2 | Benzoimidazole derivatives as anticancer agents | CENTRE LEON BERARD (FR) | 2022-07-12 | — | — | US | disclosed |
| US-20210292328-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2021-09-23 | — | — | US | disclosed |
| US-20210292328-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2021-09-23 | — | — | US | disclosed |
| CN-110234640-A | Benzimidazole derivatives as anticancer agents | 利昂贝拉尔中心 | 2019-09-13 | — | — | CN | disclosed |
| WO-2018054989-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509465-B2 | Benzoimidazole derivatives as anticancer agents | CCAR2, MAPKAP1, BCOR | KDM4E 4285/4885NPC1 1805/4885POLB 2146/4885 |
| US-20210292328-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | TMBIM6, BAX, MAPK14 | KDM4E 1838/4885NPC1 3255/4885POLB 1598/4885 |
| US-11384081-B2 | Benzoimidazole derivatives as anticancer agents | TMBIM6, BAX, MAPK14 | KDM4E 1838/4885NPC1 3255/4885POLB 1598/4885 |
| US-20220348587-A1 | Benzoimidazole Derivatives As Anticancer Agents | TMBIM6, BAX, BCL2 | KDM4E 1858/4885NPC1 3283/4885POLB 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.